Nystatin

Identification

Summary

Nystatin is a polyene ionophore antifungal used to treat cutaneous, mucocutaneous, and gastrointestinal mycotic infections, particularly those caused by Candida species.

Brand Names
Flagystatin, Nyaderm, Nyamyc, Nystop, Viaderm Kc
Generic Name
Nystatin
DrugBank Accession Number
DB00646
Background

Nystatin is a polyene antifungal drug that has broad-spectrum fungicidal and fungistatic activity against a number of yeasts and fungi, most notably Candida species.8 It is one of the most effective antifungal agents synthesized by bacteria, in this case a strain of Streptomyces noursei,13 and is closely related to amphotericin B, differing only slightly in structure.2 Nystatin has a greater antifungal activity than amphotericin B - parenterally administered nystatin, however, is associated with significant toxicity and is not available in a formulation appropriate for systemic use.2 As it undergoes very little absorption following oral or topical administration, nystatin's efficacy is limited to the treatment/prevention of cutaneous, mucocutaneous, and gastrointestinal fungal infections.8,9

Type
Small Molecule
Groups
Approved, Vet approved
Structure
Thumb
Weight
Average: 926.107
Monoisotopic: 925.503499959
Chemical Formula
C47H75NO17
Synonyms
  • Nistatina
  • NYS
  • Nystatin
  • Nystatine
  • Nystatinum

Pharmacology

Indication

Nystatin is available in oral formulations for the treatment and/or prevention of oral candidiasis (a.k.a. thrush), intestinal candidiasis, and anal candidiasis.8,9 It is indicated topically for the treatment of vulvovaginal candidiasis and other cutaneous candida infections.9 A combination product containing nystatin alongside neomycin, gramicidin D, and triamcinolone (Viaderm K.C.®) is indicated in the treatment of corticosteroid-responsive dermatoses caused by bacterial or candidal infections and for pruritus ani/vulvae.10 It is also available in combination with metronidazole for the treatment of mixed infections due to Trichomonas vaginalis and Candida albicans.13

Nystatin is also sometimes used off-label for the prevention of invasive candidiasis in low birth weight neonates,4 though it is generally reserved as a second-line option after fluconazole.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Nystatin is an antifungal that is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. It exerts its antifungal effects via disruption of the fungal cell membrane. Resistance to nystatin is minimal in Candida albicans, but tends to develop in other species of Candida.8 Nystatin carries no significant activity against bacteria, protozoa, or viruses. It carries significant systemic toxicity and is currently unavailable in a formula appropriate for systemic use - its efficacy is currently restricted, therefore, to topical, oral, and gastrointestinal infections.2

Mechanism of action

Nystatin is a channel-forming ionophore, meaning it exerts its therapeutic effect via formation of a membrane-spanning pore in the fungal plasma membrane.5 The formation of this pore results in a change in membrane permeability that allows for leakage of intracellular contents and the subsequent disruption of electrochemical gradients necessary for proper cell function.8,2 Selectivity for fungal cells over mammalian cells is due to nystatin’s greater binding affinity for ergosterol, a key sterol found in fungal cell walls, as opposed to its mammalian counterpart, cholesterol.6

TargetActionsOrganism
AErgosterol
binder
Candida albicans
Absorption

Systemic absorption of nystatin is minimal following oral administration,8 and no detectable plasma concentrations are attained following topical or vaginal administration.12

Volume of distribution

Nystatin is not absorbed into the systemic circulation8 and thus does not undergo distribution.

Protein binding

Nystatin is not absorbed into the systemic circulation8 and is therefore not subject to plasma protein binding.

Metabolism

Because nystatin undergoes little-to-no systemic absorption it is not metabolized to any appreciable extent.8

Route of elimination

The majority of orally administered nystatin is eliminated unchanged in the feces.8

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

The oral LD50 in rats is 10 g/kg.11 There have been no reports of serious toxic effects following overdosage of nystatin - doses in excess of five million units daily have resulted in nausea and gastrointestinal upset with no other associated effects.8

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AmbrisentanThe excretion of Ambrisentan can be decreased when combined with Nystatin.
AsunaprevirThe excretion of Asunaprevir can be decreased when combined with Nystatin.
AtorvastatinThe excretion of Atorvastatin can be decreased when combined with Nystatin.
AxitinibThe excretion of Axitinib can be decreased when combined with Nystatin.
Belantamab mafodotinThe excretion of Belantamab mafodotin can be decreased when combined with Nystatin.
Bempedoic acidThe excretion of Bempedoic acid can be decreased when combined with Nystatin.
BenzylpenicillinThe excretion of Benzylpenicillin can be decreased when combined with Nystatin.
BosentanThe excretion of Bosentan can be decreased when combined with Nystatin.
BrincidofovirThe serum concentration of Brincidofovir can be increased when it is combined with Nystatin.
CaspofunginThe excretion of Caspofungin can be decreased when combined with Nystatin.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Nystatin dihydrateNot AvailableNot AvailableZDFDJJJGIRGMBE-YMRVYQTRSA-N
Product Images
International/Other Brands
Adiclair (Ardeypharm) / Afunginal (Euro Generics) / Biofanal (Pfleger) / Candacide (Be-Tabs Pharmaceuticals) / Candermil (LKM) / Candex (Square) / Candidias (Fabra) / Candistat (Ambalal Sarabhai Enterprises) / Candistin (Pharos) / Canstat (Aspen Pharmacare) / Cazetin (Ifars) / Diaper NZ (Cheminter) / Dipni (Omega) / Enystin (Kalbe) / Fukangning (Deyer) / Fungatin (Ferron) / Fungicidin Leciva (Zentiva) / Fungistin (Beximco) / Fungostatin (Nobel) / Funistatin (Nobel) / Gynostatin (Iqfarma) / Kandistatin (Metiska) / Kenalon (Ta Fong) / Lederlind (Riemser) / Ledernyst (Riemser) / Lystin (Biolab) / Nilstat (Glenmark) / Nyaderm (Taro) / Nystan (Bristol Myers Squibb)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
MestatinCream25000 unit / gVaginalMedic Laboratory LtÉe1980-12-311996-09-09Canada flag
Mycostatin Oral Suspension 100000iuLiquid100000 unit / mLOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1972-12-312003-07-28Canada flag
Mycostatin Oral Tab 500000iuTablet500000 unitOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1955-12-312002-07-30Canada flag
Mycostatin Vaginal Crm 25000unitCream25000 unit / gVaginalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1973-12-312005-08-01Canada flag
Nadostine Sus 100000iu/mlSuspension100000 unit / mLOralLab Nadeau LtÉe, Division Of Technilab Inc.1974-12-312004-08-03Canada flag
Nadostine Tab 100000unitTablet100000 unitVaginalLab Nadeau LtÉe, Division Of Technilab Inc.1973-12-312004-08-03Canada flag
Nadostine Tab 500000unitTablet500000 unit / tabOralLab Nadeau LtÉe, Division Of Technilab Inc.1973-12-311999-09-28Canada flag
Nilstat 25000units/gCream25000 unit / gVaginalTechnilab Pharma Inc.1974-12-312004-08-03Canada flag
Nilstat Oral Dps 100000iu/mlSolution / drops100000 unit / mLOralLederle Cyanamid Canada Inc.1970-12-311997-01-29Canada flag
Nilstat Orl Tab 500000unitTablet500000 unit / tabOralLederle Cyanamid Canada Inc.1970-12-311997-01-29Canada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Dom-nystatin SuspensionSuspension100000 unit / mLOralDominion Pharmacal1998-08-05Not applicableCanada flag
Ftp-nystatinSolution / drops100000 unit / mLOralFtp Pharmacal Inc.1998-10-092004-08-03Canada flag
Jamp-nystatin Oral Suspension USPSuspension100000 unit / mLOralJamp Pharma Corporation2015-01-09Not applicableCanada flag
MycostatinPowder100000 [USP'U]/1gTopicalE.R. Squibb & Sons, L.L.C.2009-06-012010-03-31US flag
MycostatinCream100000 [USP'U]/1gTopicalE.R. Squibb & Sons, L.L.C.2007-01-012007-06-30US flag
NyamycPowder100000 [USP'U]/1gTopicalUpsher-Smith Laboratories, LLC2005-05-03Not applicableUS flag
NyataKit100000 U/1gTopicalCrown Laboratories2015-12-172016-10-03US flag
Nyata Nystatin PowderKit100000 U/1gTopicalCrown Laboratories2016-12-082017-01-02US flag
NystatinCream100000 [USP'U]/1gTopicalA-S Medication Solutions2006-09-212018-08-31US flag
NystatinPowder100000 1/1gTopicalLeading Pharma, Llc2018-04-23Not applicableUS flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Candistatin Topical Powder - 100000 Unit/gPowder100000 unit / gTopicalBristol Myers Squibb1996-12-312008-04-25Canada flag
Mycostatin Crm 100000unit/gmCream100000 unit / gTopicalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1970-12-312006-09-06Canada flag
Mycostatin Ont 100000iu/gmOintment100000 unit / gTopicalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1955-12-312002-07-30Canada flag
Mycostatin Topical Pwr 100,000units/gmPowder100000 unit / gTopicalConvatec, Division Of Bristol Myers Squibb Canada Co.1994-12-312008-11-12Canada flag
Nadostine Crm 100000iu/gmCream100000 unit / gTopicalLab Nadeau LtÉe, Division Of Technilab Inc.1974-12-312004-08-03Canada flag
Nadostine Ont 100000iu/gmOintment100000 unit / gTopicalLab Nadeau LtÉe, Division Of Technilab Inc.1974-12-312004-08-03Canada flag
Nilstat Top Crm 100000unit/gmCream100000 unit / gTopicalLederle Cyanamid Canada Inc.1979-12-311997-01-29Canada flag
Nilstat Top Ont 100000unit/gmOintment100000 unit / gTopicalLederle Cyanamid Canada Inc.1979-12-311997-01-29Canada flag
Nyaderm Crm 100000unit/gmCream100000 unit / gTopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada flag
Nyaderm Ont 100000unit/gmOintment100000 unit / gTopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
BABYLIND MEDICADA� CREMA T�PICA.Nystatin (100 %) + Zinc oxide (20 g)CreamTopicalLABORATORIOS DEMAC LTDA.2020-12-16Not applicableColombia flag
BABYSKIN� N CREMANystatin (2.2727 g) + Zinc oxide (40 g)CreamTopicalALTEA FARMACEUTICA S.A.2009-06-24Not applicableColombia flag
DECADRON�OVULOSNystatin (100000 IU) + Dexamethasone acetate (0.25 mg)InsertVaginalTECNOFAR TQ S.A.S2007-01-29Not applicableColombia flag
DEMTRIS® UNGUENTONystatin (100000 IU) + Neomycin (2.5 mg) + Triamcinolone acetonide (1 mg)OintmentTopicalBCN MEDICAL S.A.2016-10-04Not applicableColombia flag
DEMTRIS� CREMANystatin (10 million IU) + Neomycin (250 mg) + Triamcinolone acetonide (100 mg)CreamTopicalBCN MEDICAL S.A.2016-10-04Not applicableColombia flag
FlagystatinNystatin (100000 unit) + Metronidazole (500 mg)SuppositoryVaginalSanofi Aventis1979-12-31Not applicableCanada flag
FlagystatinNystatin (100000 unit / sup) + Metronidazole (500 mg / sup)SuppositoryVaginalAventis Pharma Ltd.1972-12-312004-07-30Canada flag
FlagystatinNystatin (100000 unit / 4.5 g) + Metronidazole (500 mg / 4.5 g)CreamVaginalSanofi Aventis1976-12-312017-08-24Canada flag
GYNECON - TNystatin (100000 IU) + Benzalkonium (7 MG) + Diiodohydroxyquinoline (100 MG)TabletVaginalบริษัท คอนติเนนเติล-ฟาร์ม จำกัด จำกัด2005-03-10Not applicableThailand flag
Kenacomb CreamNystatin (100000 unit / g) + Gramicidin D (.25 mg / g) + Neomycin sulfate (2.5 mg / g) + Triamcinolone acetonide (1 mg / g)CreamTopicalWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.1965-12-312004-08-05Canada flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
FIRST BXN MouthwashNystatin (6.75 mg/1mL) + Diphenhydramine hydrochloride (0.84 mg/1mL) + Lidocaine hydrochloride (6.75 mg/1mL)KitOralCutisPharma, Inc2009-09-08Not applicableUS flag
FIRST Dukes Mouthwash CompoundingNystatin (0.6 g/0.6g) + Diphenhydramine hydrochloride (0.525 g/0.525g) + Hydrocortisone (0.06 g/0.06g)KitOralCutisPharma, Inc.2010-12-15Not applicableUS flag
FIRST Marys Mouthwash CompoundingNystatin (1.2 g/1.2g) + Diphenhydramine hydrochloride (0.45 g/0.45g) + Hydrocortisone (0.06 g/0.06g) + Tetracycline hydrochloride (1.5 g/1.5g)KitOralCutisPharma, Inc.2010-12-15Not applicableUS flag
MIKOSTATIN 100.000 I.U./ML ORAL SÜSPANSİYON 48 MLNystatin (100000 i.u./ml)OralDeva Holding A.S.2020-08-14Not applicableTurkey flag

Categories

ATC Codes
D01AA01 — NystatinG01AA01 — NystatinA07AA02 — NystatinG01AA51 — Nystatin, combinations
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Macrolides and analogues / Hexoses / O-glycosyl compounds / Beta hydroxy acids and derivatives / Oxanes / Dicarboxylic acids and derivatives / Secondary alcohols / 1,2-aminoalcohols / Amino acids / Lactones
show 11 more
Substituents
1,2-aminoalcohol / Acetal / Alcohol / Aliphatic heteropolycyclic compound / Amine / Amino acid / Amino acid or derivatives / Aminoglycoside core / Beta-hydroxy acid / Carbonyl group
show 24 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
nystatins (CHEBI:473992)
Affected organisms
  • Fungi

Chemical Identifiers

UNII
BDF1O1C72E
CAS number
1400-61-9
InChI Key
VQOXZBDYSJBXMA-RKEBNKJGSA-N
InChI
InChI=1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-36(53)35(52)20-19-31(49)21-32(50)22-33(51)23-39(55)62-29(3)28(2)42(27)56/h5-6,8,10-18,27-38,40-44,46,49-54,56-58,61H,7,9,19-26,48H2,1-4H3,(H,59,60)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31?,32?,33?,34?,35?,36?,37?,38?,40?,41-,42+,43+,44-,46+,47+/m0/s1
IUPAC Name
(1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-{[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid
SMILES
C[C@H]1O[C@H](OC2CC3O[C@@](O)(CC(O)C3C(O)=O)CC(O)C(O)CCC(O)CC(O)CC(O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O

References

General References
  1. Akaike N, Harata N: Nystatin perforated patch recording and its applications to analyses of intracellular mechanisms. Jpn J Physiol. 1994;44(5):433-73. [Article]
  2. Dos Santos AG, Marques JT, Carreira AC, Castro IR, Viana AS, Mingeot-Leclercq MP, de Almeida RFM, Silva LC: The molecular mechanism of Nystatin action is dependent on the membrane biophysical properties and lipid composition. Phys Chem Chem Phys. 2017 Nov 15;19(44):30078-30088. doi: 10.1039/c7cp05353c. [Article]
  3. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [Article]
  4. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16. [Article]
  5. Yamasaki M, Tamura N, Nakamura K, Sasaki N, Murakami M, Rajapakshage W, Kumara B, Tamura Y, Lim SY, Ohta H, Takiguchi M: Effects and mechanisms of action of polyene macrolide antibiotic nystatin on Babesia gibsoni in vitro. J Parasitol. 2011 Dec;97(6):1190-2. doi: 10.1645/GE-2799.1. Epub 2011 Jul 14. [Article]
  6. Silva L, Coutinho A, Fedorov A, Prieto M: Competitive binding of cholesterol and ergosterol to the polyene antibiotic nystatin. A fluorescence study. Biophys J. 2006 May 15;90(10):3625-31. Epub 2006 Feb 24. [Article]
  7. Liu W, Guan X, Yu Z, Chen K, Benet L, Zhai S: A Drug-drug Interaction Between Cyclosporine and Nystatin. Clin Ther. 2018 Apr;40(4):660-662. doi: 10.1016/j.clinthera.2018.02.008. Epub 2018 Mar 16. [Article]
  8. FDA Approved Drug Products: Nystatin oral suspension [Link]
  9. DPD Approved Drugs: Nystatin [Link]
  10. DPD Approved Drugs: Viaderm K.C.® [Link]
  11. ThermoFisher Scientific: Nystatin MSDS [Link]
  12. MedSafe NZ: Nystatin [Link]
  13. DPD Approved Drugs: Flagystatin® vaginal ovules [Link]
Human Metabolome Database
HMDB0014784
KEGG Drug
D00202
KEGG Compound
C06572
PubChem Compound
11953884
PubChem Substance
46504780
ChemSpider
10468627
RxNav
7597
ChEBI
473992
ChEMBL
CHEMBL229383
Therapeutic Targets Database
DAP000879
PharmGKB
PA450666
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Nystatin
FDA label
Download (776 KB)
MSDS
Download (72.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedHealth Services ResearchEnd-stage Renal Failure (ESRF)1
4CompletedPreventionCandidiasis / Critically-ill Patients / Fungal Prophylaxis / Surgery1
4CompletedPreventionSystemic Fungal Infections1
4CompletedPreventionVery Low Birth Weight Infants1
4CompletedTreatmentPhotochemotherapy Reaction1
4CompletedTreatmentVaginal Inflammation1
4TerminatedTreatmentBurns1
4Unknown StatusPreventionAnticandidal Property of Saccharomyces Boulardii on Very Low Birth Weight Infants1
4Unknown StatusPreventionOral Mucositis1
3Active Not RecruitingTreatmentCandida albicans infection / Smoking, Cigarette1

Pharmacoeconomics

Manufacturers
  • Bayer pharmaceuticals corp
  • Bristol myers squibb co
  • Alpharma us pharmaceuticals division
  • Lederle laboratories div american cyanamid co
  • Actavis mid atlantic llc
  • Altana inc
  • Perrigo new york inc
  • Taro pharmaceuticals usa inc
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals llc
  • Westwood squibb pharmaceuticals inc
  • Bristol myers squibb
  • Barlan pharmacal co inc
  • Dava pharmaceuticals inc
  • Paddock laboratories inc
  • Coastal pharmaceuticals inc
  • Kv pharmaceutical co
  • Par pharmaceutical inc
  • Upsher smith laboratories inc
  • X gen pharmaceuticals inc
  • Warner chilcott co llc
  • Apothecon inc div bristol myers squibb
  • Glenmark generics inc usa
  • Bausch and lomb pharmaceuticals inc
  • E fougera div altana inc
  • Morton grove pharmaceuticals inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Roxane laboratories inc
  • Vintage pharmaceuticals inc
  • Vistapharm inc
  • Wockhardt eu operations (swiss) ag
  • Savage laboratories inc div altana inc
  • Mutual pharmaceutical co inc
  • Quantum pharmics ltd
  • Sandoz inc
  • Usl pharma inc
  • Watson laboratories inc
  • Holland rantos co inc
  • Odyssey pharmaceuticals inc
Packagers
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Apothecon
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Bausch & Lomb Inc.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Contract Pharm
  • Cutis Pharma Inc.
  • Dept Health Central Pharmacy
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Duramed
  • E. Fougera and Co.
  • E.R. Squibb and Sons LLC
  • Gallipot
  • Glenmark Generics Ltd.
  • Major Pharmaceuticals
  • Medisca Inc.
  • Metrics Inc.
  • Midlothian Labs
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Novopharm Ltd.
  • Nycomed Inc.
  • Odyssey Pharmaceuticals Inc.
  • Paddock Labs
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • PD-Rx Pharmaceuticals Inc.
  • PEDiNOL
  • Perrigo Co.
  • Pharmaceutical Association
  • Pharmaceutics International Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Precision Dose Inc.
  • Preferred Pharmaceuticals Inc.
  • Qualitest
  • Rebel Distributors Corp.
  • Sandoz
  • Savage Labs
  • Stat Scripts LLC
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • USL Pharma Inc.
  • Vintage Pharmaceuticals Inc.
  • Vistapharm Inc.
  • Wockhardt Ltd.
  • Xactdose Inc.
  • X-Gen Pharmaceuticals
Dosage Forms
FormRouteStrength
CreamTopical100000 IU/g
OintmentTopical100000 IU/g
SuspensionOral100000 IU/g
Tablet, film coatedOral500000 IU
GelTopical100000 IU/g
SuspensionOral
Tablet, sugar coatedOral500000 IU/1
KitTopical25 G
PasteTopical
CreamTopical100000 USP
OintmentTopical100000 USP
SuspensionOral100000 USP
GelTopical250000 USP
PasteTopical100000 USP
CreamTopical
Solution / drops; suspension / drops
SuspensionOral100000 IU/ML
KitOral
Solution / dropsOral100000 unit / mL
Powder, for suspensionOral
SuspensionOral1710.623 mg
Tablet, coatedOral500000 IU
CapsuleVaginal
SuspensionOral100 IU/L
PasteTopical100000 IU/g
CreamVaginal
InsertVaginal
SuspensionOral100000 IU
CreamVaginal
Pill
PowderTopical100000 [USP'U]/1g
Tablet, film coatedOral
SuspensionOral
OintmentTopical
PasteTopical
LiquidOral100000 unit / mL
PowderTopical100000 unit / g
SuspensionOral100000 unit / mL
TabletVaginal100000 unit
TabletOral500000 unit / tab
CreamVaginal100000 unit / g
TabletVaginal100000 unit / tab
SuspensionOral0 IU
Tablet, coatedOral
OintmentTopical2 g
InsertVaginal100 IU
TabletVaginal100 IU
SuspensionOral10000000 IU
SuspensionOral2000 mg
SuspensionOral1.94 g
CreamTopical10 millions
InsertVaginal100000 IU
SuspensionOral100 IU/ML
CreamVaginal25000 unit / g
SuppositoryVaginal
KitTopical100000 U/1g
CreamTopical100000 U/1g
CreamTopical100000 [USP'U]/1g
CreamTopical100000 mg/1g
InsertVaginal100000 [USP'U]/1
OintmentTopical100000 [USP'U]/1g
OintmentTopical100000 U/1g
OintmentTopical100000 1/1g
PowderTopical100000 1/1g
PowderTopical100000
Powder, for suspensionOral5000
SuspensionOral100000 [iU]/1mL
SuspensionOral100000 [USP'U]/1mL
SuspensionOral100000
SuspensionOral100000 [USP'U]/15mL
SuspensionOral500000 [USP'U]/5mL
TabletVaginal
Tablet, coatedOral500000 [USP'U]/1
Tablet, film coatedOral500000 [USP'U]/1
Tablet, sugar coatedOral
PowderOral
CreamTopical
OintmentTopical
SolutionOral100000 [USP'U]/1mL
Tablet, sugar coatedOral500000 IU
TabletOral
PowderTopical100000 U/1g
OintmentAuricular (otic)
KitTopical100000 [USP'U]/1g
CreamTopical100000 unit / g
OintmentTopical100000 unit / g
TabletOral500000 unit
CreamTopical2.059 g
SuppositoryVaginal
CapsuleOral
SuspensionOral100000 UNITS/1ML
Tablet, sugar coatedOral500000 UNITS
TabletVaginal100000 iu
TabletVaginal
Prices
Unit descriptionCostUnit
Nystatin 10 billion unit powder3014.1USD each
Nystatin 5 billion unit powder2096.1USD each
Nystatin 2 billion unit powder1116.9USD each
Nystatin 1 billion unit powder452.08USD each
Nystat-rx 5 billion unit powder447.0USD each
Nystatin 500 million unit powder130.75USD each
Pedi-Dri 100000 unit/gm Powder 56.7 gm Bottle105.87USD bottle
Nystatin 150mu Bottle94.5USD bottle
Nystatin 150 million unit powder42.25USD each
Nystatin 150000000 unit powder42.0USD each
Nystatin Nystatin Powder 50 Million unit Bottle39.99USD bottle
Mycostatin 100000 unit/gm Powder 15 gm Bottle36.99USD bottle
Nystop 100000 unit/gm Powder 15 gm Bottle29.99USD bottle
Nystatin 50 million unit powder19.75USD each
Nystatin 100000 unit/gm Ointment 15 gm Tube12.99USD tube
Nystatin 100000 unit/gm Cream 15 gm Tube6.5USD tube
Nystatin 100000 unit tablet5.29USD tablet
Nystatin vaginal tablet5.0USD tablet
Pedi-dri topical powder1.82USD g
Nystop 100000 unit/gm powder1.6USD g
Nystatin 500000 unit tablet0.71USD tablet
Nystatin 500000 unit oral tablet0.68USD tablet
Mycostatin 500000 unit orl tablet0.48USD tablet
Nystatin 100000 unit/ml Suspension0.25USD ml
Ratio-Nystatin 500000 unit Tablet0.25USD tablet
Nystatin 100000 unit/gm cream0.1USD g
Pms-Nystatin 100000 unit/ml Suspension0.05USD ml
Ratio-Nystatin 100000 unit/ml Suspension0.05USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)160 °C (decomposes)MSDS
water solubility360 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.086 mg/mLALOGPS
logP-3.1ALOGPS
logP-1.9ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.61ChemAxon
pKa (Strongest Basic)9.11ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count12ChemAxon
Polar Surface Area319.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity243.55 m3·mol-1ChemAxon
Polarizability99.93 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.8641
Blood Brain Barrier-0.9581
Caco-2 permeable-0.741
P-glycoprotein substrateSubstrate0.5182
P-glycoprotein inhibitor INon-inhibitor0.814
P-glycoprotein inhibitor IINon-inhibitor0.6721
Renal organic cation transporterNon-inhibitor0.96
CYP450 2C9 substrateNon-substrate0.8313
CYP450 2D6 substrateNon-substrate0.867
CYP450 3A4 substrateNon-substrate0.5273
CYP450 1A2 substrateNon-inhibitor0.916
CYP450 2C9 inhibitorNon-inhibitor0.9374
CYP450 2D6 inhibitorNon-inhibitor0.9354
CYP450 2C19 inhibitorNon-inhibitor0.9243
CYP450 3A4 inhibitorNon-inhibitor0.931
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.987
Ames testNon AMES toxic0.8992
CarcinogenicityNon-carcinogens0.9731
BiodegradationNot ready biodegradable0.8601
Rat acute toxicity2.1245 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9462
hERG inhibition (predictor II)Non-inhibitor0.8971
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Small molecule
Organism
Candida albicans
Pharmacological action
Yes
Actions
Binder
References
  1. Silva L, Coutinho A, Fedorov A, Prieto M: Competitive binding of cholesterol and ergosterol to the polyene antibiotic nystatin. A fluorescence study. Biophys J. 2006 May 15;90(10):3625-31. Epub 2006 Feb 24. [Article]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [Article]

Drug created on June 13, 2005 13:24 / Updated on July 23, 2021 16:02